News Focus
News Focus
icon url

pollyvonwog

08/05/10 12:29 PM

#100850 RE: jmkobers #100849

correct
icon url

rkrw

08/05/10 12:33 PM

#100852 RE: jmkobers #100849

It doesn't work like that. Teva isn't getting approval as a non substitutable product without running clinical trials.
icon url

Mpower

08/05/10 12:57 PM

#100858 RE: jmkobers #100849

In the event of a non-substitutable approval for TEVA, MNTA sole-generic royalty structure would remain in-tact.

Sanofi AG decision would depend on what Sanofi wants to do ... i suspect they would refrain from a AG in such a scenario.

Please refer to Dew's Readmefirst for more detailed discussion around the aforementioned scenario.